Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT

Breast Cancer Female Clinical Trial

Official title:

Selective Omission of Axillary Surgery in Distinct Responders With Triple-negative and HER2-positive Breast Cancer After NACT

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05314114
• Other study ID #: BC-P29
• Status: Recruiting
• Phase: N/A
• Start date: July 3, 2020
• Est. completion date: September 2028

Study information

• Verified date: April 2022
• Source: Peking University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Neoadjuvant chemotherapy (NACT) is standard treatment for many triple-negative (TNBC) and HER2-positive breast cancer. Study showed about half of the biopsy-proven axillary disease will be eradicated by NACT and converted to ypN0 indicating the efficacy of systemic treatment in local disease control.

According to current guidelines, all initial cN0 patients will undergo sentinel lymph node biopsy (SLNB) after NACT and further axillary dissection (ALND) if tumor residual is discovered after SLNB. Data suggest patients who underwent SLNB have a significantly higher rate of disability in the early post-operative period compared to patients who did not and the avoidance of SLNB might translate into a considerable reduction of physical and emotional distress. Recent studies revealed the association between breast pCR and ypN0 status after NACT. Initially cN0 TNBC and HER2-positive breast cancer patients who achieve pCR in breast after NACT have a very low risk of positive lymph node residual and are very unlikely to benefit from further axillary surgery including SLNB.

The investigators designed a clinical trial to test the hypothesis that selective omission of axillary surgery in distinct responders after NACT will not deteriorate survival. In the planned trial, axillary surgery will be completely eliminated for initially cN0 TNBC and HER2-positive breast cancer patients who achieve pCR in breast after NACT determined by lumpectomy.

The trial is designed as a prospective, single-center, single-arm study with a limited number of patients (N=136). Patients will be recruited in China over a period of 36 months. Our results, together with other ongoing studies in other parts of the world with a similar design, might give practice-changing results and spare the time and the costs of a randomized comparison.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 136
• Est. completion date: September 2028
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Written informed consent

• Core biopsy confirmed unicentric primary invasive triple-negative or HER2-positive breast cancer. Multifocal or multicentric tumors allowed only if breast-conserving surgery is deemed feasible.

• At least 18 years of age

• Initial tumor stage cT1c-T3N0M0 prior to NACT. cN0 stage established by clinical examination and ultrasonography

• In cases with suspicious lymph node, a negative core biopsy or fine needle aspiration (FNA) biopsy of the sonographically suspected lymph node is required

• Standard NACT with evident radiologic response

• Planned breast-conserving surgery with postoperative external whole-breast irradiation

Exclusion Criteria:

• History of previous malignancy

• Histologically proven N1 patients, patients with distant metastasis (M1)

• Pregnant or lactating patients

• Inflammatory breast cancer

• Radiologically non-responsive after NACT

• Mastectomy planned after NACT

• planned intraoperative radiotherapy (e.g. Intrabeam) or postoperative partial breast irradiation (e.g. multicatheter technique) alone; both procedures are allowed as boost techniques

• Written informed consent not obtained

Related Conditions & MeSH terms

• Breast Cancer Female
• Breast Neoplasms

Intervention

Procedure:
• No axillary surgery
No axillary surgery

Locations

Country	Name	City	State
China	Peking University Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ipsilateral axillary recurrence-free survival	time between randomization and confirmed ipsilateral axillary recurrence	5-year
Secondary	locoregional lymph node recurrence-free survival	time between randomization and confirmed locoregional lymph node recurrence	5-year
Secondary	distant metastasis-free survival	time between randomization and confirmed distant metastasis	5-year